Sodium Chloride 0.9% & Lidocaine 0.4% in Dextrose 5%
January 25, 2012
Hospira has voluntarily recalled specific lots of sodium chloride 0.9% injection and lidocaine hydrochloride 0.4% in dextrose 5% injection, as a result of out of specification results during lot testing. No adverse events have been reported with the affected products so far. The affected products were distributed between November 2010 and September 2011 and the corresponding lot numbers are listed below.
- 0.9% Sodium Chloride Injection, USP, 250 mL, NDC 0409-7983-02
- Lot number 94-833-KL (may be followed by 01, 02 or 03)
- Expiration date: October 2012
- 0.4% Lidocaine hydrochloride and 5% Dextrose Injection, USP, 250mL, NDC 0409-7931-32
- Lot number 92-643-KL (may be followed by 01, 02 or 03)
- Expiration date: February 2012
Do not use the affected products. Return all affected products to Stericycle. To request return labels visit http://expertezlabel.com or contact Stericycle at 1-866-204-6110. Unaffected lots of sodium chloride 0.9% injection and lidocaine hydrochloride 0.4% in dextrose 5% injection are available for replacement. Contact Hospira Customer Care at 1-877-946-7747 to obtain replacement product. For medical questions regarding this recall, contact Hospira Medical Communications at 1-800-615-0187. Contact Hospira Global Product Safety and Complaints at 1-800-441-4100 with any questions regarding product quality compliance, reasons for the recall, or to report an adverse event associated with one of the recalled products. Report adverse events to FDA’s MedWatch Adverse Event Reporting program online at https://www.accessdata.fda.gov/scripts/medwatch/medwatch-online.htm.
January 25, 2012; University of Utah, Drug Information Service. Copyright 2012, Drug Information Service, University of Utah, Salt Lake City, UT.